In summary, the combination regimen of toripalimab with chemotherapy for treatment-naïve patients with advanced NSCLC lacking EGFR/ALK driver mutations led to better OS compared to chemotherapy alone. This evidence concerns the gene ALK and non-small cell lung carcinoma.